ATE405654T1 - Polypeptid mit verbesserter cytosin-deaminase- aktivität - Google Patents

Polypeptid mit verbesserter cytosin-deaminase- aktivität

Info

Publication number
ATE405654T1
ATE405654T1 AT04744156T AT04744156T ATE405654T1 AT E405654 T1 ATE405654 T1 AT E405654T1 AT 04744156 T AT04744156 T AT 04744156T AT 04744156 T AT04744156 T AT 04744156T AT E405654 T1 ATE405654 T1 AT E405654T1
Authority
AT
Austria
Prior art keywords
polypeptide
activity
deeaminase
cytosine
improved
Prior art date
Application number
AT04744156T
Other languages
English (en)
Inventor
Philippe Erbs
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE405654T1 publication Critical patent/ATE405654T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04744156T 2003-07-21 2004-06-29 Polypeptid mit verbesserter cytosin-deaminase- aktivität ATE405654T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03360087 2003-07-21
US50827403P 2003-10-06 2003-10-06

Publications (1)

Publication Number Publication Date
ATE405654T1 true ATE405654T1 (de) 2008-09-15

Family

ID=39719832

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04744156T ATE405654T1 (de) 2003-07-21 2004-06-29 Polypeptid mit verbesserter cytosin-deaminase- aktivität

Country Status (16)

Country Link
US (3) US7790445B2 (de)
EP (2) EP1897938B9 (de)
JP (1) JP4672659B2 (de)
KR (1) KR101062140B1 (de)
CN (1) CN1826410B (de)
AT (1) ATE405654T1 (de)
AU (1) AU2004257935B2 (de)
CA (1) CA2532783C (de)
CY (1) CY1110397T1 (de)
DE (1) DE602004015995D1 (de)
DK (1) DK1649023T3 (de)
ES (1) ES2311831T3 (de)
IL (1) IL173158A (de)
PL (1) PL1649023T3 (de)
PT (1) PT1649023E (de)
WO (1) WO2005007857A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2029756T3 (en) 2006-06-20 2017-02-13 Transgene Sa PROCEDURE FOR PREPARING POXVIRA AND POXVIRUS COMPOSITIONS
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
JP5421250B2 (ja) 2007-07-03 2014-02-19 トランスジーン ソシエテ アノニム トリ不死化細胞株
CN102227503B (zh) * 2008-09-26 2015-10-21 托卡根公司 重组载体
US8609392B2 (en) 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
IN2012DN01577A (de) 2009-07-21 2015-06-05 Transgene Sa
EP2527432A1 (de) * 2011-05-23 2012-11-28 Novozymes A/S Bidirektionaler Cytosin-Deaminase-codierender Selektionsmarker
WO2013004658A1 (en) 2011-07-01 2013-01-10 Transgene Sa Formulations of 5-fluorocytosine and uses thereof.
US9642921B2 (en) 2012-12-20 2017-05-09 Tocagen Inc. Cancer combination therapy and recombinant vectors
WO2015155263A1 (en) 2014-04-10 2015-10-15 Transgene S.A. Poxviral oncolytic vectors
RU2696312C2 (ru) 2014-07-16 2019-08-01 Трансген Са Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
KR102507483B1 (ko) 2014-12-01 2023-03-07 트랜스진 안정한 액체 백시니아 바이러스 제제
EP4523756A3 (de) 2015-02-13 2025-05-28 Transgene Immunotherapeutischer impfstoff und antikörperkombinationstherapie
WO2017135800A1 (ko) * 2016-02-05 2017-08-10 주식회사 에스엘바이젠 Trail 및 cd를 발현하는 중간엽줄기세포 및 이의 용도
CA3023022A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US20190336552A1 (en) 2016-05-30 2019-11-07 Astellas Pharma Inc. Genetically engineered vaccinia viruses
WO2017209053A1 (ja) * 2016-05-30 2017-12-07 アステラス製薬株式会社 新規な遺伝子組換えワクシニアウイルス
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
CA3093093A1 (en) 2018-03-07 2019-09-12 Transgene Parapoxvirus vectors
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3858369A4 (de) 2018-09-26 2022-07-20 Astellas Pharma Inc. Krebstherapie, bei der onkolytisches vaccinia-virus und immun-checkpoint-inhibitor in kombination verwendet werden, und pharmazeutische zusammensetzung und darin verwendetes kombinationsarzneimittel
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
US20260049291A1 (en) 2022-08-18 2026-02-19 Transgene Chimeric poxviruses

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
FR2583429B1 (fr) * 1985-06-18 1989-11-03 Transgene Sa Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u
CA2018273C (en) 1989-06-09 1999-04-06 Peter D. Senter Thermally stable cytosine deaminase
US5358866A (en) 1991-07-03 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Cytosine deaminase negative selection system for gene transfer techniques and therapies
ATE178490T1 (de) 1993-02-16 1999-04-15 Onyx Pharmaceuticals Cytopathische viren zur therapie und prophylaxe der neoplasie
AU6953394A (en) * 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
FR2722208B1 (fr) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
FR2737222B1 (fr) 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2759382A1 (fr) 1997-02-10 1998-08-14 Transgene Sa Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
FR2762615B1 (fr) 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
FR2777570A1 (fr) * 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US6552005B1 (en) * 1998-09-29 2003-04-22 Uab Research Foundation Molecular chemotherapy enhancement of radiotherapy
US20030121068A1 (en) * 2001-11-30 2003-06-26 Paul Orchard Vector encoding suicide and marker constructs
US7141404B2 (en) 2002-12-27 2006-11-28 Onyx Pharmaceuticals, Inc. Candida kefyr cytosine deaminase

Also Published As

Publication number Publication date
CY1110397T1 (el) 2015-04-29
EP1649023B1 (de) 2008-08-20
EP1897938B9 (de) 2011-08-31
US20100330031A1 (en) 2010-12-30
CA2532783C (en) 2013-09-17
PT1649023E (pt) 2008-11-20
JP2006527994A (ja) 2006-12-14
HK1112024A1 (en) 2008-08-22
US8257692B2 (en) 2012-09-04
ES2311831T3 (es) 2009-02-16
US20100330051A1 (en) 2010-12-30
KR101062140B1 (ko) 2011-09-05
CA2532783A1 (en) 2005-01-27
WO2005007857A1 (en) 2005-01-27
US8226954B2 (en) 2012-07-24
AU2004257935B2 (en) 2009-11-19
JP4672659B2 (ja) 2011-04-20
DK1649023T3 (da) 2008-10-06
CN1826410A (zh) 2006-08-30
PL1649023T3 (pl) 2009-01-30
EP1897938A1 (de) 2008-03-12
CN1826410B (zh) 2011-10-26
EP1649023A1 (de) 2006-04-26
IL173158A0 (en) 2006-06-11
EP1897938B1 (de) 2010-10-06
AU2004257935A1 (en) 2005-01-27
US7790445B2 (en) 2010-09-07
DE602004015995D1 (de) 2008-10-02
IL173158A (en) 2009-12-24
US20070264235A1 (en) 2007-11-15
HK1084150A1 (en) 2006-07-21
KR20060040697A (ko) 2006-05-10

Similar Documents

Publication Publication Date Title
ATE405654T1 (de) Polypeptid mit verbesserter cytosin-deaminase- aktivität
ATE417595T1 (de) Keratin-bindende polypeptide
DK1651166T3 (da) Polypeptid til induktion af et beskyttende immunrespons mod staphylococcus aureus
DK2327719T3 (da) Hybrid- og tandemekspression af neisseria-proteiner
DK1454138T3 (da) Immunocytokiner med moduleret selektivitet
EP1496123A4 (de) Acetolactatsynthase codierende gene
EA201200398A1 (ru) Полипептиды с оксидоредуктазной активностью и их применение
BRPI0517493A (pt) polinucleotìdeo isolado, promotor vetor de expressão, célula hospedeira e uso de um polinucleotìdeo
NO20063026L (no) Antistoffer
NZ774126A (en) Spd-1 variant - fc fusion proteins
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
EA200801464A1 (ru) Способ и система для компенсации вызванного внутренними причинами смещения ткани
ATE462000T1 (de) Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin
EP4374913A3 (de) Neuartiger humaner serumalbuminmutant
DE60237791D1 (de) Zytokinproteinfamilie
DE50213015D1 (de) Lipase-varianten
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
NO20082864L (no) Nytt polypeptid med esteraseaktivitet og rekombinant esterase samt anvendelse derav
EP1467207A4 (de) Screening-verfahren
SE0101519D0 (sv) Nucleic ACID
DE602005025989D1 (de) Von 2',3'-didesoxynucleosiden und 2',3'-didehydro-2',3'-didesoxynucleosiden
ATE387494T1 (de) Hitzelabile desoxyribonuklease i-varianten
ATE454401T1 (de) Il-18bp promoter herstellung und verwendung
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
TW200617021A (en) Isolated photoprotein aequorin y89f, and its use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1649023

Country of ref document: EP